The research discussed in this presentation seeks to understand recent changes to the availability of naloxone and opioid agonist treatment, as well as the far-reaching consequences of the COVID-19 pandemic. The analyses draw on qualitative and quantitative methods to explore what constitutes enabling environments to improve the health of people who use opioids.
 |
Anna Conway Anna Conway is a Research Associate in the Viral Hepatitis Clinical Research Program at the Kirby Institute. Her research interests include drug use, drug treatment, and hepatitis C. Anna’s research draws on epidemiology and social sciences to explore barriers to health and wellbeing at the program and policy levels. |
Opinions expressed by individuals at this event are solely of those of the individual/s and do not necessarily represent the views or opinions of the Kirby Institute or UNSW.